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Abstract: Schizophrenia is a debilitating psychotic mental disorder that affects almost the entire 
range of human mental function. The devastating effect of the illness is usually long-lasting and 
requires lifelong treatment. Despite an evolved psychopharmacological understanding, the over-
all therapeutic effect of antipsychotics is still not satisfactory. The choice of proper medication 
presents a clinical dilemma between efficacy and safety. As a result, searching for comparable 
treatment options with safer profiles is very important. Yokukansan (TJ-54), also called yi-gan san 
in Chinese, is a traditional herbal medicine with evident therapeutic effect for neuropsychiatric 
disorders. There are several open-label clinical studies upholding the possibility of using yoku-
kansan to treat schizophrenia or schizophrenia-like psychosis. Evidence from animal studies and 
neurobiology also sheds light on the antipsychotic implications of yokukansan and its ingredients. 
Nevertheless, correlations between the experimental environment and clinical settings may be 
complicated by a number of confounders. Clinical trials with more sophisticated designs are 
required to fill the gap between the experimental environment and clinical settings.
Keywords: herbal medicine, geissoschizine methyl ether, glycyrrhizin, antipsychotics, D2 
receptor
Background
Schizophrenia is often a severe and debilitating psychotic disorder. It usually begins 
in late adolescence or early adulthood and affects approximately 1% of the popula-
tion.1 The devastating effect of the illness is usually long-lasting and requires lifelong 
treatment. Considering the substantial burden on patients, their families, and society, 
schizophrenia is becoming one of the most important public health problems.1 The 
core symptoms and signs of the illness include hallucinations, delusions, abnormal 
behaviors, and disorganized speech. Deficits in the ability to experience pleasure, flat-
tening of emotional expression, loss of drive, and impoverishment of mental activity 
are also noticed. Vocational and social disabilities usually result from the accompanied 
cognitive impairments in memory, attention, and executive function.2 Almost the entire 
range of human mental function is affected by the disorder. 
People with schizophrenia have difficulties in regulating information. They are 
unable to filter out the stimuli that most people can ignore3 and lack the skills to assess 
their significance.4 Together with the paranoid psychopathology, patients become 
hypervigilant and struggle to decide what experiences are real.5 Violence in response 
to these symptoms may occur,6 as can suicidal behaviors.7 There are several patho-
logical processes of the brain that express schizophrenia as a disease of the mind. The 
unfortunate convergence of these factors results in altered neurotransmitter mechanisms 
and loss of neuronal connectivity, both of which contribute to deficits in inhibitory 
function and the inability to sort information.5 Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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Antipsychotics
Antipsychotics are the primary treatments for schizophrenia. 
Since the first discovery of the neuroleptic effects of chlorpro-
mazine in the 1950s, modulation of dopamine D2 receptors 
has played an important role in treating psychotic disorders.8 
Along with the similar modulation, newer-generation antip-
sychotics have been developed since the enhanced treatment 
effect of clozapine was reported in 1988.9 The pharmacologi-
cal picture has also evolved, from understanding of simple 
blockade of D2 receptors to combined dopamine–serotonin 
antagonism, to even more advanced functionally selective 
actions at dopamine receptors.10–12 Nonetheless, the overall 
therapeutic effect is not satisfactory. Around one-fifth to 
one-third of patients with schizophrenia do not respond 
adequately to typical antipsychotics.13 The Clinical Antipsy-
chotic Trials of Intervention Effectiveness (CATIE) showed 
that none of the examined medications could provide the 
majority of patients with a treatment they were able to tolerate 
for the full study period.14,15 Although olanzapine was found 
to be slightly superior to the conventional and other novel 
agents in terms of the Positive and Negative Syndrome Scale 
(PANSS) ratings,14 and clozapine was found to diminish the 
frequency of suicidal behavior, including serious suicidal 
acts,15 both clozapine and olanzapine are more likely to 
cause severe weight gain and potentially fatal metabolic 
problems.16,17 Patients with schizophrenia not only exhibit 
higher prevalence of metabolic syndrome, but are also at 
greater risk for developing cardiovascular mortality than the 
general population.18,19 Choosing proper medication is always 
a clinical dilemma. As a result, searching for comparable 
treatment options with safer profiles is very important. 
Yokukansan
Traditional herbal medicines have drawn a lot of attention in 
recent decades regarding the balance between effectiveness 
and side effects.20–24 They have been utilized for a long time in 
the People’s Republic of China and oriental countries, Japan, 
  Taiwan, Korea and Vietnam. Herbal remedies were first 
introduced into Japan as Kampo medicine in the 5th century 
and have been modified over hundreds of years in Japan.25 
  Yokukansan (TJ-54), also called yi-gan san in Chinese, is one 
of the Kampo prescriptions and has evident therapeutic effects 
for neuropsychiatric disorders. It contains a mixture of seven 
dried herbs, including Angelica acutiloba L. (Umbelliferae), 
Atractylodes lancea DC. (Compositae), Bupleurum falcatum 
L. (Umbelliferae), Poria cocos Wolf. (Polyporaceae), Glycyr-
rhiza uralensis (Leguminosae), Cnidium officinale Makino 
(Umbelliferae), and Uncaria rhynchophylla Schreb. (Rubi-
aceae) in a ratio of 3:4:2:4:1.5:3:3, respectively26 (Table 1). 
The mixed extract is sold in packages with 2.5 g per unit and 
is usually taken three times daily before meals.25 Yokukansan 
was developed in 1555 by Xue Kai as a treatment for agitation 
and restlessness in children,20 and has been used in Japan for 
indications of insomnia, neurosis, irritability in children, and 
behavioral and psychological symptoms of dementia.22,27–30 
Because of accumulating reports of yokukansan in treating 
psychiatric disorders,31 there is an emphasis on establishing 
its clinical implication in schizophrenia and schizophrenia-
like psychotic symptoms (Table 2).
Following the observation that yokukansan may have 
beneficial effects on dyskinesia,32 Miyaoka et al performed 
a 12-week, open-label study examining its efficacy, safety, 
and tolerability as an adjunctive treatment in 22 schizo-
phrenic patients with tardive dyskinesia (TD).33 They 
found statistical improvement not only of TD, but also of 
psychotic symptoms. Transient nausea and constipation 
were reported in only two cases. However, after yokukansan 
was stopped, the condition of TD deteriorated.33 In order to 
evaluate its antipsychotic effects, the same group performed 
a 4-week, open-label control study to assess the usefulness 
of adding yokukansan in treating refractory patients with 
schizophrenia.34 A significant decrease was observed in 
each subscale in PANSS ratings by the end of 4 weeks. 
Mild nausea or tiredness were noticed in three cases, but 
no serious adverse events were reported. This result sug-
gests that an adjunction of yokukansan might be effective 
for treatment-resistant schizophrenia.34 Furthermore, based 
on an experience of successful treatment of visual hal-
lucination due to vision loss,35 a 4-week, open-label study 
was initiated to investigate the monotherapeutic effect of 
yokukansan in treating Charles Bonnet Syndrome (CBS).36 
A significant decrease of visual hallucination was revealed 
by psychometrics, including the Neuropsychiatric Inven-
tory (NPI), the hallucination subscale of the PANSS, and 
Clinical Global Impression (CGI). CBS is defined by the triad 
of ocular pathology causing visual deterioration, complex 
visual hallucinations, and preserved cognitive status. The 
hypothetical pathophysiology is the deafferentation theory, 
which means a loss of sensory input after damage to neurons 
Table 1 Components of yokukansan
Constituent herb Ratio of constituent*
Angelica acutiloba L. (roots) 3
Atractylodes lancea DC. (roots) 4
Bupleurum falcatum L. (roots) 2
Poria cocos wolf. (fungus) 4
Glycyrrhiza uralensis (roots) 1.5
Cnidium officinale Makino (roots) 3
Uncaria rhynchophylla Schreb. (hooks) 3
Note: *These are the ratios relative to each other.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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leading to excessive response of the deafferented neurons.37 
In the central nervous system, this results in cortical hyper-
excitability, a similar phenomenon observed in mechanisms 
of schizophrenia-like psychosis.5 There is no established 
treatment for CBS. The positive result of these trials support 
Yokukansan as possible treatment for psychosis. 
Recently, a more naturalistic 4-week, open-label study 
of yokukansan monotherapy for very-late-onset schizo-
phrenia was conducted.38 Considerable improvement of 
psychotic symptomatology was noticed in all 40 patients. 
The statistically significant reduction on psychopathology 
was shown in all measures, including the Brief Psychiat-
ric Rating Scale (BPRS), CGI-Severity, and the PANSS. 
Scores on the Simpson-Angus Scale, Barnes Akathisia 
Rating Scale, and Abnormal Involuntary Movement Scale 
(AIMS) decreased slightly but not significantly. There was 
no impairment in overall cognitive function as measured 
by the Mini-Mental State Examination (MMSE). These 
preliminary results   demonstrate the possibility that yoku-
kansan could be an effective and safe treatment option for 
schizophrenia.
Evidence from animal studies and neurobiology also 
sheds light on the antipsychotic implications of yokukansan. 
Several neurotransmitter systems involved in the neuro-
psychiatric effects of yokukansan and its ingredients have 
important roles in schizophrenia. Yokukansan was reported 
to inhibit the increased release of glutamate in zinc-deficient 
rats, which was regarded as a neurological disease model with 
the perturbed glutamatergic neurotransmitter system, and a 
modulation function on excitatory neurotransmitters was 
suggested.39 A further study revealed that yokukansan exerted 
a neuroprotective effect by ameliorating the dysfunction of 
glutamate transporters in astrocytes.40 This was mediated by 
one of the constituents of yokukansan, G. uralensis, and its 
main metabolite, 18β-glycyrrhetinic acid, which can access 
the brain through the blood–brain barrier.41,42 However, 
Table 2 Clinical trials using yokukansan for patients with schizophrenia and schizophrenia-like psychosis
Study,  
year
Sample size and  
study design
Average daily  
dosage (g/day) mean ± 
standard deviation
Assessment Adverse events
Miyaoka,33  
2008
13 males
9 females
Mean age: 57.1 years
12-week open-label study
Adjunctive therapy
7.5 AiMS (12.1±2.2-.1.6±1.3)**
PANSS:   Positive (22.2±4.2-.16.6±3.1)** 
Negative (26.5±6.3-.14.5±2.3)** 
General (42.9±6.7-.25.0±4.9)**
CGi-S (4.86±0.9-.1.73±0.6)**
Nausea and  
constipation (2 cases)
Miyaoka,34  
2009
Treatment group
16 males
18 females
Mean age: 45.5 years
Control group
10 males
15 females
Mean age: 45.2 years
4-week open-label control study
Adjunctive therapy
6.7±2.5 PANSS:   Positive (27.7±6.1-.11.9±3.7)** 
Negative (30.4±5.8-.18.2±2.2)** 
General (65.1±5.4-.39.6±6.9)**
DiePSS (7.8±4.7-.6.9±4.1) 
Nausea (2 cases)
Tiredness (1 case)
Miyaoka,35  
2009
A 2-week-treatment case report
Monotherapy
7.5  Self-report  No adverse events 
reported 
Miyaoka,36  
2011
7 males
13 females
Mean age: 66.3 years
4-week open-label study
Monotherapy
5.8±2.6 NPi (20.4±2.4-.5.4±1.5)**
HS-PANSS (6.4±2.4-.1.6±1.2)**
CGi (4.5±1.8-.1.3±0.3)**
Nausea (3 cases)
Miyaoka,38  
2013
20 males
20 females
Mean age: 73.1 years
4-week open-label study
Monotherapy
Baseline
5.02±1.06 
week 4
5.23±1.22 
BPRS (36.7±4.65-.20.1±1.6)*
CGi-S (5.03±0.89-.1.73±0.55)*
PANSS (66.0±7.3-.34.3±2.2)*
Simpson-Angus Scale (0.27±0.45-.0.15±0.36) 
Barnes Akathisia Rating Scale  
(0.20±0.41-.0.13±0.34)
AiMS (0.23±0.42-.0.18±0.39)
Tremor (3 cases)
Notes: *P0.001, **P0.0001.
Abbreviations: AiMS, Abnormal involuntary Movement Scale; BPRS, Brief Psychiatric Rating Scale; CGi, Clinical Global impression; CGi-S, CGi-Severity; DiePSS, Drug-
induced extrapyramidal Symptom Scale; HS-PANSS, hallucination subscale of the PANSS; NPi, Neuropsychiatric inventory; PANSS, Positive and Negative Symptom Scale.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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excessive release of glutamate not only induces neuronal 
death, as described in neurodegenerative disorders,43 but also 
enhances the frequency of excitatory postsynaptic potentials 
in cortical pyramidal cells, as observed in schizophrenia.5,44 
These processes might be reversed by yokukansan in some 
way. 
Repeated administration of yokukansan was found 
to decrease expression of 5-hydroxytryptamine (5-HT)2A 
receptors in the prefrontal cortex and inhibit the head-twitch 
response induced by serotonin 5-HT2A/2C receptor agonist in 
mice.45 These results suggest the involvement of the serotonin 
system in the psychopharmacological effects of yokukansan. 
Constituent analysis of yokukansan revealed that compounds 
with affinities for 5-HT1A, 5-HT2A, 5-HT2C, and 5-HT7 were 
only contained in U. rhynchophylla.46 Further study demon-
strated that geissoschizine methyl ether, a corynanthean-type 
alkaloid contained in U. rhynchophylla, had high blood–brain 
barrier permeability47 and behaved as a partial agonist at the 
serotonin 5-HT1A receptor and as an antagonist at the sero-
tonin 5-HT2A, 5-HT2C, and 5-HT7 receptors.48 
Geissoschizine methyl ether
Geissoschizine methyl ether is an indole alkaloid with a 
β-carboline structure, also called methyl (16Z,19E)-16-
(methoxymethylidene)coryn-19-en-17-oate (Figure 1). The 
molecular formula is C22H26N2O3, and its molecular weight is 
366.4534. β-carboline derivatives have been shown to have 
different affinities at different 5-HT receptors, depending 
on their ring substituents and ring saturation.49 An in vivo 
experiment also showed that geissoschizine methyl ether 
could ameliorate isolation-induced increased aggressiveness 
and decreased sociality, a function thought to be related 
to 5-HT1A agonist.50 Atypical antipsychotics often exhibit 
serotonergic properties, especially 5-HT2A and 5-HT2C 
receptor antagonism.10
 Activation of the 5-HT1A receptor 
has been suggested to decrease extrapyramidal symptoms 
and increase dopaminergic neurotransmission in the frontal 
cortex.51 Although the clear role for the 5-HT7 receptor is not 
fully understood, blockade of it could be useful in treatment 
of psychotic symptoms,52 and some atypical antipsychotics, 
such as clozapine and risperidone, express high antagonistic 
affinity for this receptor. 
Besides its serotonergic function, geissoschizine methyl 
ether has also been reported to be a partial agonist/antagonist 
at the cloned dopamine D2Long receptors with a low intrinsic 
activity and a partial activation response.48 All these qualities 
are similar to the properties found in aripiprazole. Aripiprazole, 
a so-called third-generation antipsychotic, acts on D2Long-
mediated signaling pathways with multiple intrinsic activities. 
This functionally selective profile, combined with actions at 
other neurotransmitter systems, was suggested to be respon-
sible for the development of novel antipsychotics.11 Moreover, 
yokukansan has been proven to increase central acetylcholine 
release,53 and this atypical antipsychotic-like property may be 
helpful in preserving cognitive ability in schizophrenia.54
Adverse events
Some reversible adverse events of yokukansan have been 
reported, including sedation,22 vomiting/diarrhea, nausea, 
epigastric discomfort, leg edema, and hypokalemia.28 Gly-
cyrrhizin, contained in G. uralensis, is able to facilitate 
potassium excretion in the renal tubules, and this may 
result in hypokalemia.28 There are no metabolic side effects 
documented. On the contrary, a large epidemiological study 
disclosed that the prevalence of diabetes was significantly 
increased for patients who received clozapine, olanzap-
ine, and quetiapine.55 Nonetheless, Izumi et al found that 
yokukansan was able to suppress lipid synthesis and reduce 
fat accumulation in adipocytes by modulating the transcrip-
tion factors without affecting glucose uptake.56 Considering 
the increased metabolic problems in patients with schizophre-
nia, choosing a drug without aggravation of lipid metabolism 
is essential in clinical practice. 
Conclusion
This review of the literature highlights the possibility of 
yokukansan and its ingredients as new treatment options for 
schizophrenia. Nevertheless, correlations between the experi-
mental environment and clinical settings may be complicated 
by a number of confounders. In order to bridge between basic 
Figure 1 Chemical structure of geissoschizine methyl ether.
Notes: Molecular formula: C22H26N2O3. Molecular weight: 366.4534 g/mol.
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research and clinical applications, further studies with more 
sophisticated designs are necessary.
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